Loading clinical trials...
Loading clinical trials...
1. Further characterize the incidence of hyperfibrinolysis in cirrhotics 2. Correlate hyperfibrinolysis with 1. hepatitis C 2. alcoholic liver disease 3. the subset of a\&b with renal failure with and without dialysis 3. Better describe the hyperfibrinolytic ROTEM profile in cirrhotics
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University of Utah
Salt Lake City, Utah, United States
Start Date
November 1, 2015
Primary Completion Date
April 1, 2017
Completion Date
April 1, 2017
Last Updated
November 8, 2017
54
ACTUAL participants
Rotem
OTHER
Lead Sponsor
Scott Allen
NCT05597488
NCT06932783
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06306963